The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics

Overview of attention for article published in Multiple Sclerosis Journal, February 2006

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Readers on

mendeley: 153 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Alemtuzumab for treating relapsing‑remitting multiple sclerosis: Multiple sclerosis (relapsing-remitting) - alemtuzumab: evaluation report

Cited by National Institute for Health and Care Excellence (NICE) on 05 Dec 2013

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.